Ultrafiltration device shown safe, effective and reduces hospital stay for heart failure patients

September 22, 2003

LAS VEGAS, NV. -- Sept. 22, 2003 -- Data presented as a poster at this year's Heart Failure Society of America meeting in Las Vegas, NV, showed that ultrafiltration using CHF Solutions' System 100 Fluid Removal System is a safe and effective means to remove large volumes of excess fluid in patients with heart failure, and also reduces hospital length of stay by almost two days when compared to the national average of patients receiving conventional diuretic treatment. Data also demonstrated that System 100 ultrafiltration treatment lead to improved B-type natriuretic peptide (BNP) levels and other overall health benefits that were substantial enough to improve patients' heart failure ranking on the New York Heart Association's (NYHA) classification scale (the medical community's gold standard for measuring level of heart failure).

The observational study was conducted by Midwest Heart Specialists, one of the largest private cardiology practices in Illinois, who observed 25 heart failure patients receiving ultrafiltration with the System 100 in order to assess the effectiveness of the device on fluid-overload. Dr. Mitchell T. Saltzberg and Dr. Maria Rosa Costanzo led the study at four Midwest Heart affiliated hospital sites; Good Samaritan Hospital, Edwards Hospital, Central DuPage Hospital, and Elmhurst Memorial Hospital.

"Conventional diuretic treatments have been frustrating to doctors due to unpredictable results and treatment times," said Dr. Maria Rosa Costanzo, a Heart Failure Specialist at Midwest Heart Specialists. "The System 100 provides doctors the confidence and ability to remove a specific fluid amount within a set timeframe, thus providing the patient more immediate and complete relief as well as improving the overall standard of hospital cardiac care."

Many health conditions such as kidney failure, post-surgical overload and metabolic diseases such as glucose intolerance, hyperglycemia and acid maltase can cause fluid-overload, however congestive heart failure (CHF) is the leading cause. CHF Solutions' System 100 is approved for use to treat fluid-overload in all these types of patients. There are 550,000 new cases of congestive heart failure each year and 2.2 million fluid-overloaded CHF patients are hospitalized yearly, costing the U.S. healthcare system more than $23 billion annually.

"Results showed that ultrafiltration with the System 100 in patients with heart failure shortened hospital length of stay by two days compared to the national average observed in the ADHERE1 study," added Dr. Mitchell T. Saltzberg, Medical Director of the Heart Failure Program at Midwest Heart Specialists. "The positive results indicate that the System 100 may be a more efficient and economical treatment for this patient population."

Additionally, study observations showed that patients experienced a 158+289 pg/dl drop in B-type natriuretic peptide (BNP) levels, a protein secreted by the heart when under volume or pressure overload. Measurement of BNP via a simple blood test helps diagnose heart failure and its severity. Thus a decrease in BNP levels indicates improvement in heart health. Patients also lost an average of five pounds (primarily water) during the System 100 ultrafiltration treatment, reducing the amount of excess weight straining the heart and in many cases enabling patients to be more mobile and active.

"The System 100 Fluid Removal System is designed to create a win-win situation, resulting in improved medical outcomes while allowing patients to leave the hospital earlier," explained John L. Erb, Chief Executive Officer of CHF Solutions, Inc. "This means the expedient delivery of top-notch cardiac care with a potential cost savings for both the patient and hospital alike."

The System 100 is manufactured by CHF Solutions, Inc. a Minnesota-based manufacturer of innovative medical devices for cardiac care. It received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) in June 2002 and has since incorporated into the premier cardiac programs of hospitals across the United States, including some of the nation's top hospitals as rated by U.S. News & World Report.

The findings of Midwest Heart's observational study were used to set the scientific protocols for their EUPHORIA2 trial that is currently underway. Euphoria's primary efficacy and safety end points are to determine whether early System 100 ultrafiltration of diuretic-resistant patients upon hospital admission can completely resolve fluid overload signs and symptoms to achieve hospital discharge within three days without the development of adverse metabolic changes such as renal insufficiency or symptomatic hypotension. Secondary endpoints measured (at discharge, one month and three months) will include whether early System 100 ultrafiltration decreases diuretic resistance, improves cost effectiveness compared to historical treatments, reduces the need for short-term re-hospitalization, and improves how patients feel earlier in their hospitalization.

These observations by Midwest Heart Specialists come on the heels of the successful Simple Access Fluid Extraction (SAFE) clinical trial, which demonstrated that the System 100 could safely, and effectively remove fluid overload via peripheral catheters rather than central venous catheters. This, among other things, enables healthcare providers other than physicians to administer the treatment. Data from the SAFE trial was submitted to the FDA and used as the basis for approval of the System 100 in June, 2002.

"The SAFE clinical trial showed that the System 100 offers patients and physicians an effective treatment option for fluid-overload," said Dr. Brian E. Jaski, lead investigator of the SAFE trial at Sharp Memorial Hospital in San Diego, California.
About CHF Solutions & The System 100 Fluid Removal System
Headquartered in Brooklyn Park, Minnesota, CHF Solutions is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the System 100 Fluid Removal System. The System 100 Fluid Removal System is a technologically sophisticated, yet easy-to-use mechanical pump/ultrafiltration system that can remove up to four liters (one gallon) of excess fluid from the body over an eight-hour treatment. Physicians can specify and adjust the exact amount and rate of fluid to be removed from each patient, resulting in a gradual reduction that has no significant clinical impact on electrolyte balance, blood pressure or heart rate. A standard midline catheter for vascular access is established via a patient's peripheral vein, typically the arm, and the System 100 is administered. This is a closed system which processes blood through the filtration console via inflow and outflow catheters in the patient's arms. The system can be used in conjunction with or as an alternative to diuretic or inotropic drug therapies to achieve the target fluid removal goal for the patient. And, because it resets fluid levels, the System 100 may also improve the effectiveness of oral diuretics that patients take on an ongoing basis. For more information, visit www.chfsolutions.com.

About Midwest Heart Specialists (MHS)
Midwest Heart Specialists is a 50-member private practice cardiology group in Chicago. Among the group's cardiac sub-specialties are congestive heart failure, electrophysiology, lipid management, interventional cardiology, radiology and clinical diagnosis and treatment. MHS physicians are on staff at nine greater Chicago hospitals and at additional clinics in Aurora, Yorkville, BolingBrook, Kishwaukee and Sandwich. For more information, visit www.midwestheart.com.

1. Acute Decompensated Heart Failure National Registry

2. Early Ultrafiltration Therapy in Patients with Decompensated Heart Failure and Observed Resistance to Intervention with Diuretic Agents

FischerHealth, Inc.

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.